Sanofi (NASDAQ:SNY) Shares Sold by Patten Group Inc.

Patten Group Inc. cut its holdings in Sanofi (NASDAQ:SNY) by 27.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 12,187 shares of the company’s stock after selling 4,692 shares during the quarter. Patten Group Inc.’s holdings in Sanofi were worth $588,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of SNY. Synergy Asset Management LLC purchased a new stake in shares of Sanofi in the fourth quarter valued at about $25,000. McClarren Financial Advisors Inc. boosted its holdings in shares of Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares in the last quarter. Sunbelt Securities Inc. boosted its holdings in shares of Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after acquiring an additional 313 shares in the last quarter. Sierra Ocean LLC purchased a new stake in shares of Sanofi in the fourth quarter valued at about $44,000. Finally, Versant Capital Management Inc purchased a new stake in shares of Sanofi in the fourth quarter valued at about $54,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Up 2.1 %

SNY stock opened at $57.70 on Wednesday. The company has a market cap of $146.43 billion, a P/E ratio of 23.17, a P/E/G ratio of 1.01 and a beta of 0.57. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. The company’s 50-day moving average price is $52.00 and its 200 day moving average price is $52.64. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, research analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.